Literature DB >> 9123879

Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein.

A Ruggieri1, T Harada, Y Matsuura, T Miyamura.   

Abstract

We have characterized viral-cell interactions of hepatitis C virus (HCV) and liver cells to study the pathogenesis of HCV infection. HepG2 cells constitutively expressing HCV core protein showed apoptotic changes in response to stimulation with anti-Fas monoclonal antibody. Cells treated with the antibody showed extensive cell rounding, shrinkage, and cytoplasmic blebbing and finally detached from plates. Fragmentation of the chromatin was observed in the nucleus and DNA ladders were detected. In contrast, cells expressing HCV envelope, nonstructural proteins or normal HepG2 cells did not exhibit such Fas-mediated apoptosis. However, expression of Fas receptor was not upregulated on the surface of the cells expressing HCV core protein. Apoptotic cell death was prevented by pretreatment with a specific inhibitor of the cysteine protease CPP32, while the specific inhibitor of interleukin-1 beta-converting enzyme did not show the preventive effect. The results suggest (i) that intracellular expression of HCV core protein makes cells prone to apoptotic death without upregulation of surface Fas expression and (ii) that the CPP32 protease plays a part in the apoptosis effector pathway of HCV core-expressing cells. HCV core protein may have a role in immune-mediated liver cell injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9123879     DOI: 10.1006/viro.1996.8420

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 2.  Apoptosis: a mechanism of acute and chronic liver injury.

Authors:  M E Guicciardi; G J Gores
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Oxidative stress and apoptosis in hepatitis C: the core issue.

Authors:  Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

4.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 5.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

6.  The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1.

Authors:  Nur Khairiah Mohd-Ismail; Lin Deng; Sunil Kumar Sukumaran; Victor C Yu; Hak Hotta; Yee-Joo Tan
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 7.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

8.  Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus.

Authors:  Koichi Watashi; Makoto Hijikata; Ayako Tagawa; Takahiro Doi; Hiroyuki Marusawa; Kunitada Shimotohno
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

9.  Inhibition of core gene of HCV 3a genotype using synthetic and vector derived siRNAs.

Authors:  Saba Khaliq; Shah Jahan; Bushra Ijaz; Waqar Ahmad; Sultan Asad; Asim Pervaiz; Baila Samreen; Mahwish Khan; Sajida Hassan
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

10.  Hepatitis C virus and its roles in cell proliferation.

Authors:  Kunitada Shimotohno; Koichi Watashi; Katsuya Tsuchihara; Katsuhiko Fukuda; Hiroyuki Marusawa; Makoto Hijikata
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.